Literature DB >> 18929711

Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions.

Dmitry Abramov1, Rose S Cohen, Stuart D Katz, Donna Mancini, Mathew S Maurer.   

Abstract

Anemia is a significant co-morbidity in patients with heart failure (HF) irrespective of the ejection fraction and is routinely quantified by hemoglobin concentration. Hemodilution as a cause of anemia has been described in systolic HF. The aim of this study was to further investigate the effects of plasma volume in patients with HF by (1) assessing the prevalence of dilutional anemia in patients with anemia and preserved ejection fractions and (2) exploring the relation between hemoglobin and red cell volume in these patients. Forty-six patients with anemia (as determined by standard hemoglobin measurement), 22 with HF and low ejection fractions (HFLEF) and 24 with HF and preserved ejection fractions (HFPEF), all underwent plasma volume measurement with iodine-131-labeled albumin. Hemoglobin values did not differ between subjects with HFLEF and those with HFPEF (10.8 +/- 1.0 vs 11.0 +/- 1.0 g/dl, p = 0.55), but a red cell deficit was found in 88% of patients with HFPEF compared with 59% of those with HFLEF (p = 0.04). This was the result of a higher prevalence of an expansion of plasma volume in patients with HFLEF (100%) compared with those with HFPEF (71%). Among all patients, no correlation was found between hemoglobin and red cell volume (r = 0.09, p = 0.54), but a correlation did exist in patients with normal blood volumes (r = 0.55, p = 0.02). In conclusion, dilutional anemia caused by an expansion in plasma volume without a red cell deficit occurs more commonly in patients with HFLEF than those with HFPEF, and hemoglobin does not correlate with red cell volume in patients with anemia and HF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929711      PMCID: PMC2583148          DOI: 10.1016/j.amjcard.2008.05.058

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia.

Authors:  Peter L Johansson; Soodabeh Safai-Kutti; Jack Kutti
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

Review 2.  Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options.

Authors:  Yi-Da Tang; Stuart D Katz
Journal:  Circulation       Date:  2006-05-23       Impact factor: 29.690

3.  Anemia and heart failure a new pathway?

Authors:  Gary S Francis; Anne Kanderian
Journal:  J Am Coll Cardiol       Date:  2007-10-23       Impact factor: 24.094

4.  Comparison of red cell and whole blood volume as performed using both chromium-51-tagged red cells and iodine-125-tagged albumin and using I-131-tagged albumin and extrapolated red cell volume.

Authors:  Howard J Dworkin; Mary Premo; Stuart Dees
Journal:  Am J Med Sci       Date:  2007-07       Impact factor: 2.378

Review 5.  Blood volume analysis: a new technique and new clinical interest reinvigorate a classic study.

Authors:  Timothy A Manzone; Hung Q Dam; Daniel Soltis; Vidya V Sagar
Journal:  J Nucl Med Technol       Date:  2007-05-11

6.  Treatment of anaemia in chronic heart failure--optimal approach still unclear.

Authors:  Niamh F Murphy; Kenneth McDonald
Journal:  Eur Heart J       Date:  2007-08-17       Impact factor: 29.983

7.  Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.

Authors:  Luís Beck-da-Silva; Luís Eduardo Rohde; Antônio Carlos Pereira-Barretto; Denílson de Albuquerque; Edimar Bocchi; Fábio Vilas-Boas; Lídia Zytynzki Moura; Marcelo W Montera; Salvador Rassi; Nadine Clausell
Journal:  J Card Fail       Date:  2007-02       Impact factor: 5.712

8.  Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.

Authors:  Jorge Eduardo Toblli; Alejandra Lombraña; Patricio Duarte; Federico Di Gennaro
Journal:  J Am Coll Cardiol       Date:  2007-10-23       Impact factor: 24.094

9.  Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

Authors:  Alberto Palazzuoli; Donald S Silverberg; Francesca Iovine; Anna Calabrò; Maria S Campagna; Maddalena Gallotta; Ranuccio Nuti
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

10.  Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.

Authors:  Jalal K Ghali; Inder S Anand; William T Abraham; Gregg C Fonarow; Barry Greenberg; Henry Krum; Barry M Massie; Scott M Wasserman; Marie-Louise Trotman; Yan Sun; Beat Knusel; Paul Armstrong
Journal:  Circulation       Date:  2008-01-14       Impact factor: 29.690

View more
  18 in total

1.  Heart failure with a normal ejection fraction: treatments for a complex syndrome?

Authors:  Samuel Bernard; Mathew S Maurer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Blood volume measurements in patients with heart failure and a preserved ejection fraction: implications for diagnosing anemia.

Authors:  Bassel Noumi; Sergio Teruya; Say Salomon; Stephen Helmke; Mathew S Maurer
Journal:  Congest Heart Fail       Date:  2011-01-24

3.  A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction.

Authors:  Arman Altincatal; Robert B Macarthur; Sergio Teruya; Stephen Helmke; Mathew S Maurer
Journal:  Cardiovasc Ther       Date:  2011-08-26       Impact factor: 3.023

4.  Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the heart failure with preserved ejection fraction (HFPEF) anemia trial.

Authors:  Margarita Borovka; Sergio Teruya; Julissa Alvarez; Stephen Helmke; Mathew S Maurer
Journal:  J Card Fail       Date:  2013-10       Impact factor: 5.712

Review 5.  Heart failure with preserved ejection fraction: a nephrologist-directed primer.

Authors:  Baris Afsar; Patrick Rossignol; Loek van Heerebeek; Walter J Paulus; Kevin Damman; Stephane Heymans; Vanessa van Empel; Alan Sag; Alan Maisel; Mehmet Kanbay
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 6.  The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome.

Authors:  Donald S Silverberg
Journal:  Heart Fail Rev       Date:  2011-11       Impact factor: 4.214

7.  Peripheral Venous Hemoglobin and Red Blood Cell Mass Mismatch in Volume Overload Systolic Heart Failure: Implications for Patient Management.

Authors:  Wayne L Miller; Brian P Mullan
Journal:  J Cardiovasc Transl Res       Date:  2015-09-08       Impact factor: 4.132

8.  Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance).

Authors:  Melissa C Caughey; Christy L Avery; Hanyu Ni; Scott D Solomon; Kunihiro Matsushita; Lisa M Wruck; Wayne D Rosamond; Laura R Loehr
Journal:  Am J Cardiol       Date:  2014-09-28       Impact factor: 2.778

9.  Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.

Authors:  Mathew S Maurer; Sergio Teruya; Bibhas Chakraborty; Stephen Helmke; Donna Mancini
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

10.  Change in plasma volume and prognosis in acute decompensated heart failure: an observational cohort study.

Authors:  Sarah R Hudson; Daniel Chan; Leong L Ng
Journal:  J R Soc Med       Date:  2016-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.